News | May 15, 2024
Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Lupin updates on shipment of Mirabegron ER Tablets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
